Wang QD - Search Results

1

Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.

Uriuda Y, Wang QD, Grip L, Rydén L, Sjöquist PO, Mattsson C. Uriuda Y, et al. Among authors: wang qd. Cardiovasc Res. 1996 Aug;32(2):320-7. doi: 10.1016/0008-6363(96)00114-9. Cardiovasc Res. 1996. PMID: 8796119

2

Beneficial effects of H290/51, a new lipid peroxidation inhibitor, on functional recovery after ischemia and reperfusion in isolated cold-arrested rat hearts.

Wang QD, Uriuda Y, Li XS, Nordlander R, Sjöquist PO, Rydén L. Wang QD, et al. J Cardiovasc Pharmacol. 1995 Jun;25(6):924-9. doi: 10.1097/00005344-199506000-00010. J Cardiovasc Pharmacol. 1995. PMID: 7564337

3

Local overflow and enhanced tissue content of endothelin following myocardial ischaemia and reperfusion in the pig: modulation by L-arginine.

Wang QD, Hemsén A, Li XS, Lundberg JM, Uriuda Y, Pernow J. Wang QD, et al. Cardiovasc Res. 1995 Jan;29(1):44-9. Cardiovasc Res. 1995. PMID: 7895238

4

Myocardial release of endothelin (ET) and enhanced ET(A) receptor-mediated coronary vasoconstriction after coronary thrombosis and thrombolysis in pigs.

Wang QD, Uriuda Y, Pernow J, Hemsén A, Sjöquist PO, Rydén L. Wang QD, et al. J Cardiovasc Pharmacol. 1995 Nov;26(5):770-6. doi: 10.1097/00005344-199511000-00014. J Cardiovasc Pharmacol. 1995. PMID: 8637192

5

Coronary venous drug infusion in the ischaemic-reperfused isolated rat heart.

Uriuda Y, Wang QD, Li XS, Sjoquist PO, Nordlander R, Ryden L. Uriuda Y, et al. Among authors: wang qd. Cardiovasc Res. 1996 Jan;31(1):82-92. Cardiovasc Res. 1996. PMID: 8849592

6

Myocardioprotective effects of felodipine in an antihypertensive dosage: an experimental study in pigs.

Shimizu M, Wang QD, Sjöquist PO, Nordlander R, Rydén L. Shimizu M, et al. Among authors: wang qd. Cardiovasc Drugs Ther. 1998 Mar;12(1):37-45. doi: 10.1023/a:1007733313553. Cardiovasc Drugs Ther. 1998. PMID: 9607131

7

Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.

Uriuda Y, Wang QD, Hatori N, Nordlander R, Sjöquist PO, Mattsson C, Rydén L. Uriuda Y, et al. Among authors: wang qd. J Pharmacol Toxicol Methods. 1998 Mar;39(2):81-9. doi: 10.1016/s1056-8719(98)00006-9. J Pharmacol Toxicol Methods. 1998. PMID: 9694166

8

Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury.

Shimizu M, Wang QD, Sjöquist PO, Rydén L. Shimizu M, et al. Among authors: wang qd. J Cardiovasc Pharmacol. 1998 Aug;32(2):231-8. doi: 10.1097/00005344-199808000-00010. J Cardiovasc Pharmacol. 1998. PMID: 9700985

9

The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts.

Shimizu M, Wang QD, Sjöquist PO, Rydén L. Shimizu M, et al. Among authors: wang qd. J Cardiovasc Pharmacol. 1999 Jul;34(1):78-81. doi: 10.1097/00005344-199907000-00013. J Cardiovasc Pharmacol. 1999. PMID: 10413071

10

Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.

Shimizu M, Wang QD, Sjöquist PO, Rydén L. Shimizu M, et al. Among authors: wang qd. J Cardiovasc Pharmacol. 1999 Oct;34(4):512-7. doi: 10.1097/00005344-199910000-00006. J Cardiovasc Pharmacol. 1999. PMID: 10511125

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters